THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS

THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS

Bibliographic Details
Main Authors:	Yew, S, Jayne, D, Westman, K, Hoglund, P, Flossman, O, Mahr, A, Luqmani, R, Robson, J
Format:	Conference item
Published:	2012

Similar Items

THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
by: Yew, S, et al.
Published: (2012)

Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials.
by: Robson, J, et al.
Published: (2015)

Damage in the ANCA-associated vasculitides: Long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials
by: Robson, J, et al.
Published: (2015)

TREATMENT-RELATED DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
by: Robson, J, et al.
Published: (2013)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
by: Suppiah, R, et al.
Published: (2011)

Long-term survival of ANCA-associated vasculitis
by: Flossmann, O, et al.
Published: (2009)

Cardiovascular outcomes in ANCA associated vasculitis
by: Mukhtyar, C, et al.
Published: (2008)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
by: Suppiah, R, et al.
Published: (2011)

FACTORS ASSOCIATED WITH LONG-TERM DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF COHORTS FROM THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
by: Robson, J, et al.
Published: (2013)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
by: Suppiah, R, et al.
Published: (2011)

Long-term patient survival in ANCA-associated vasculitis.
by: Flossmann, O, et al.
Published: (2011)

Long-term patient survival in ANCA-associated vasculitis
by: Flossmann, O, et al.
Published: (2011)

Long-term patient survival in ANCA-associated vasculitis.
by: Flossmann, O, et al.
Published: (2011)

Diagnosis and management of ANCA associated vasculitis.
by: Berden, A, et al.
Published: (2012)

Outcome measures in ANCA-associated vasculitis.
by: Suppiah, R, et al.
Published: (2010)

Comparison of disease activity measures for ANCA-associated vasculitis.
by: Merkel, P, et al.
Published: (2004)

Damage assessment in ANCA-associated vasculitis.
by: Bhamra, K, et al.
Published: (2012)

Maintenance of clinical remission in ANCA-associated vasculitis.
by: Luqmani, R
Published: (2013)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
by: Jones, R, et al.
Published: (2010)

ANCA-Associated Vasculitis: An Update
by: Salem Almaani, et al.
Published: (2021-04-01)

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
by: Robson, J, et al.
Published: (2014)

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
by: Yates, M, et al.
Published: (2016)

EULAR/ERA-EDTA RECOMMENDATIONS FOR THE MANAGEMENT OF ANCA-ASSOCIATED VASCULITIS
by: Yates, M, et al.
Published: (2016)

Explaining fatigue in ANCA-associated vasculitis
by: Basu, N, et al.
Published: (2013)

Explaining fatigue in ANCA-associated vasculitis.
by: Basu, N, et al.
Published: (2013)

Cutaneous manifestations of ANCA-associated vasculitis
by: Chiesafuxench, Z, et al.
Published: (2016)

Opinion: Maintenance of clinical remission in ANCA-associated vasculitis
by: Luqmani, R
Published: (2013)

Predictors of renal involvement in ANCA associated vasculitis
by: Kronbichler, A, et al.
Published: (2018)

Markers for work disability in ANCA-associated vasculitis
by: Basu, N, et al.
Published: (2013)

ANCA Associated Vasculitis Subtypes: Response [Letter]
by: Merkel PA, et al.
Published: (2022-09-01)

Health-related quality of life in patients with ANCA-associated vasculitis: a pooled analysis of four randomized clinical trials
by: Walsh, M, et al.
Published: (2009)

OP0053 Eular/ERA-EDTA Recommendations for The Management of Anca-Associated Vasculitis
by: Yates, M, et al.
Published: (2016)

Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
by: Jones, R, et al.
Published: (2009)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
by: Luqmani, R, et al.
Published: (2007)

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
by: Merkel, P, et al.
Published: (2009)

The characterisation and determinants of quality of life in ANCA associated vasculitis
by: Basu, N, et al.
Published: (2014)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
by: Basu, N, et al.
Published: (2012)

The characterisation and determinants of quality of life in ANCA associated vasculitis.
by: Basu, N, et al.
Published: (2014)

ANCA-associated vasculitis: Where can we go from here?
by: Luqmani, R
Published: (2010)

Immunopathogenesis of ANCA-Associated Vasculitis
by: Andreas Kronbichler, et al.
Published: (2020-10-01)